New combo therapy aims to improve leukemia outcomes in older adults

This Phase 2 trial tests whether adding venetoclax to a chemotherapy regimen of cladribine, low dose cytarabine, and azacitidine can improve remission rates in adults aged 50 and older with untreated acute myeloid leukemia. The study involves 145 participants and uses a two-stage design to evaluate how well the combination works. The goal is to find a more effective treatment option for patients who may not tolerate standard intensive chemotherapy.